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INTRODUCTION
Thyroid hormones (THs) have been
known to affect energy metabolism
(calorigenic effect) for over a century
(Magnus-Levy, 1895; Thompson et al.,
1929). In 1985 Magnus-Levy observed
that patients with mixedema exhibited
an abnormal low oxygen consumption
when compared to normal individuals
and that unusually higher amount of
oxygen was consumed by hyperthyroid
patients. 3,3′,5-triiodo-L-thyronine (T3)
is the active form of THs and it is a major
regulator of growth and development and
of cellular and tissue metabolism (both
intermediate and energy metabolism)
throughout the body. Metabolic actions
include regulation of: basal metabolic rate
in homeotherms, synthesis of mitochon-
drial respiratory enzymes andmembranes,
oxidative phosphorylation and energy
transduction, movement of water andNa+
ions across cell membranes; calcium and
phosphorus metabolism, lipids synthe-
sis and storage, catabolism of fatty acids,
cholesterol, carbohydrate; and nitrogen
(urea, creatine) metabolism; growth and
developmental actions include actions on:
rate of postnatal growth of many mam-
malian and avian tissue, maturation of
fetal brain and bone, amphibian larval
metamorphosis, and molting in birds. It
is now recognized that T3 affects gene
expression in target tissues/cells by bind-
ing to its cognate nuclear receptors (TR)
which are ligand-inducible transcription
factors. Two TR genes α and β encode
four T3-binding receptor isoforms (α1,
β1, β2, and β3). The transcriptional activ-
ity of TRs is regulated at multiple levels.
Besides being regulated by T3, transcrip-
tional activity is also regulated: (i) by
the type of thyroid hormone response
elements located on the promoters of T3
target genes, (ii) by the developmental-
and tissue-dependent expression of TR
isoforms, and (iii) by a host of nuclear
coregulatory proteins (corepressors and
coactivators). These nuclear proteins
modulate the transcription activity of TRs
in a T3-dependent manner. In the absence
of T3, corepressors act to repress the basal
transcriptional activity, whereas in the
presence of T3, coactivators act to activate
transcription. The activities regulated via
the previous described mechanisms are
described as “genomic actions.” However,
between the mid-1980’s and the begin-
ning of the 1990’s it became evident that
some TH effects are non-genomic in ori-
gin. Indeed, high-affinity binding sites for
thyroid hormones have for many years
been recognized on the plasma membrane
and other cellular sites such as mitochon-
dria and cytoplasm (for review see Cheng
et al., 2010). Recently, a structural pro-
tein of the plasma membrane, integrin
αvβ3, has been shown to contain a bind-
ing domain for iodothyronines that is an
initiation site for hormone-directed com-
plex cellular events, such as cell division
and angiogenesis (Bergh et al., 2005) and
this qualifies the binding site for char-
acterization as a receptor. Examples of
non-genomic action of thyroid hormones
are activation of: membrane Ca2-ATPase
activity, 2-Deoxyglucose transport, Na,
K-ATPase activity, Na+ current in myocar-
diocytes, Na+ current in sensory neuron,
Na+/H+ exchanger, cancer cell prolifera-
tion, angiogenesis (for review see Cheng
et al., 2010). In addition to this, it is now
recognized that other iodothyronines or
THs analogs/derivatives are able to exert
relevant biological actions (for recent
review, see Moreno et al., 2008; Senese
et al., 2014; Zucchi et al., 2014). This arti-
cle is particularly intended to describe the
effects of the 3,5 diiodo-L-thyronine (T2)
on energy balance (Moreno et al., 1997;
Goglia, 2005).
3,5-DIIODO-L-THYRONINE (T2)
T2, a naturally occurring diiodothyronine,
is a product of a currently unknown enzy-
matic process most probably utilizing T3
as its precursor (Moreno et al., 2002).
Some years ago surprising results were
published showing that (among a lot of
iodothyronines tested) T2, at a very low
concentration (pM), induced a rapid stim-
ulation of oxygen consumption in per-
fused livers isolated from hypothyroid rats.
In the same study, it was shown that
T3 showed a similar effect but this effect
was largely abolished by the addition of
an inhibitor of D1 deiodinase, while the
effect of T2 was not. Moreover, T2 exerted
its effect more rapidly than T3 (Horst
et al., 1989). Stimulated by that report
and another study showing an interaction
of a diiodothyronine with mitochondria
(Goglia et al., 1981) some laboratories
started to investigate more deeply on pos-
sible specific biological actions of T2.
Initially, energy metabolism was the major
area of interest. Indeed, several reports
from various laboratories showed that
acute or chronic administration of T2
to rats resulted in significant changes in
energy metabolism. When either T3 or
T2 were acutely injected to hypothyroid
rats, T2 had a more rapid effect on rest-
ing metabolic rate than T3 (Lanni et al.,
1996). The experimental design used in
this study was basically the same as that
employed by Tata in the early 1960’s (Tata
et al., 1962; Tata, 1963) and the only dif-
ference was that in the study of Lanni
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et al. hypothyroidism was achieved by the
simultaneous administration of propylth-
iouracil (PTU) and iopanoic acid (IOP).
This treatment produces animals with
severe hypothyroidism and at the same
time, with a powerful inhibition of all
three types of deiodinase enzymes. In such
conditions the effects of T2 were evident
as soon as 1 h after its injection reaching
the maximal value after 24 h, while that of
T3 became evident only after 24 h reaching
the maximal value after 72 h (these effects
of T3 were overlapping to those obtained
by Tata, 1963). Moreover, while the effect
of T3 was inhibited by a inhibitor of tran-
scription such as actinomycin D (as shown
also by Tata, 1963). the effect of T2 was not
(Lanni et al., 1996; Moreno et al., 1997)
(see Figure 1).
Following these results studies con-
tinued to try to clarify the mechanisms
underlying the previous described results.
In light of the effects of T2 on energy
metabolism, the mitochondria became
the obvious candidates to study such
mechanisms. In this context, some years
ago, by top-down elasticity analysis, it
was showed a stimulation of the activity
of both cytochrome c-oxidizers and the
cytochrome c-reducers components of the
respiratory chain, 1 h after the injection
of 3,5-T2 (Lombardi et al., 1998). These
data indicate a possible direct interaction
of T2 with some components of the respi-
ratory chain. Indeed, this hypothesis was
FIGURE 1 | Time course of variation in the resting metabolic rate of hypothyroid rats
following administration of a single dose of iodothyronines (25μg/100g BW for both T2 and
T3) with or without a concomitant administration of actinomycin D (8μg/100g BW) (AD).
Hypothyroidism was induced by combined treatment with PTU and IOP (P + I). Resting metabolic
rate (RMR) is reported as % increase [vs. time 0 (immediately before the injection)].
in agreement with previous results show-
ing a direct stimulation of the enzyme
cytochrome oxidase (COX) activity iso-
lated from bovine heart (Goglia et al.,
1994). Arnold and Kadenbach (1997)
showed that (in addition to the mito-
chondrial membrane potential, the sub-
strate pressure in the respiratory chain and
the oxygen concentration) the respiration
of animal cells is also controlled by the
matrix ATP/ADP ratio, via an interaction
of nucleotides with COX. In fact, ATP pro-
duces an allosteric inhibition of the COX
activity. In a further investigation, Arnold
et al. (Arnold et al., 1998) showed that
3,5-T2 specifically binds to subunit Va of
the COX complex and completely abol-
ishes the allosteric inhibition of respira-
tion induced by ATP. Subunit Va of the
COX complex is therefore a mitochondrial
site through which T2 may directly affect
mitochondrial activities. In addition to
activating mitochondrial substrate oxida-
tion, 3,5-T2 also stimulates skeletal muscle
mitochondrial uncoupling in a very rapid
manner (Lombardi et al., 2007, 2009). By
discriminating between proton-leak and
redox-slip processes, an increased mito-
chondrial proton conductance has been
addressed as the “pathway” underlying the
effect of T2 on mitochondrial uncoupling.
Thus, activation of COX complex above
described associated to changes in the effi-
ciency of the skeletal muscle mitochon-
drial energy-transduction apparatus, may
explain, at least in part, the rapid effect of
T2 on metabolic rate.
The stimulatory effects exerted by T2
on RMR prompted my group to investi-
gate on a possible effect of this iodothy-
ronine in counteracting overweight and
lipid accumulation without deleterious
side effects in particular on hearth and
skeletal muscle such as those showed by
T3 when tested as slimming agent. To
test this idea, we administered T2 for 30
days to rats on a high fat diet (HFD)
and then we measured the adipose tis-
sue mass, the body weight gain, the liver
adiposity, the liver fatty acid oxidation
rate, and the serum levels of triglyceride,
fatty acids, and cholesterol. In this study
we also looked at a possible effect of
T2 on HPT axis (Lanni et al., 2005).
The results showed that, except a slight
decrease (−20%) in T4 serum level, no
variation in the Hypothalamus-Pituitary-
Thyroid axis (HPT) was evident mea-
sured by the “TRH-test.” In this study rats
treated with T2 showed lower body weight,
a higher liver fatty acid oxidation rate,
less fat mass, an almost complete disap-
pearance of fat from the liver, and signif-
icant reductions in the serum triglyceride
and cholesterol levels. Recently, most of
these results have been confirmed also in
animals with a standard laboratory diet
and with a prolonged time of treatment
(Padron et al., 2014). In addition, several
studies from both our and others labora-
tories showed relevant biological effects of
T2 and some of them reported beneficial
effects of T2, among others:
Moreno et al. (2011) and de Lange et al.
(2011) showed that T2 prevented high-
fat-diet-induced insulin resistance in
rat whose action involved activation of
sirtuin 1 (SIRT1).
Markova et al. (2013) showed an
antidepressant-like effect of T2 in rats
after a bolus administration of T2 at the
doses 75 and 150μg/100 g b.w.
Shang et al. (2013) showed that T2
was a protective agent against renal
damage in diabetic nephropathy in
streptozotocin-induced diabetic rats,
confirming the involvement of sirtuin 1
(SIRT1).
These effects were observed in absence
of deleterious side effects. However, some
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studies have shown some deleterious effect
at cardiac level and onHPT axis (Goldberg
et al., 2012; Jonas et al., 2014) but in these
studies unusual very high doses of T2 were
studied and unspecific interaction of T2
with nuclear TRs may have occurred.
Further details about the actions of T2
can be found in some reviews (Goglia,
2005; Coppola et al., 2014; Senese et al.,
2014).
Of Note, the understanding of the
physiological and pathophysiological role
of T2 would benefit from development and
standardization of new methods for ana-
lytical measurement of T2 and other TH
derivatives. Actually, measurements of T2
in human tissue and sera have been so
far taken using immunoassays (Kirkegaard
et al., 1981; Nishikawa et al., 1981).
However, the lack of labeled iodothy-
ronines with high specific activity as well
as of specific antibodies has represented an
important limitation to the application of
such approach. Promising developments
in this field have recently emerged from the
optimization of a new competitive chemi-
luminescence immunoassay (CLIA) based
on the use of one selected mouse mon-
oclonal anti-T2 antibody with very low
cross-reactivity to structurally related THs
and thyronamines (Lehmphul et al., 2014).
Mass spectrometry techniques have also
drawn attention to the analyses of iodothy-
ronines (Köhrle et al., 2013), however,
intrinsic instrumental limits still restrain
the application of such approaches as
routine tools.
CONCLUSION AND PERSPECTIVES
The data reported and discussed in this
article have generated a large inter-
est in the possibility of identifying
analogs/derivatives of thyroid hormone
that may prove effective as therapeutic
agents to counteract some major diseases
that are growing in importance world-
wide. But, before this perspective can be
realized further studies are needed to elu-
citade the cellular/molecular mechanisms
of action of these agents and, in addi-
tion, a possible therapeutic use of these
agents need deep investigations on possi-
ble deleterious side effects especially when
administered for a long time. As for T2 it
remains to be established whether it has a
physiological role or not and in an affir-
mative case it remains unclear what are
the possible physiological roles that differ-
entiate the actions of T2 and T3. Another
aspect is related to the problem of pos-
sible TR-mediated genomic effect of T2.
It has been recently proven that T2 is a
specific ligand for a long isoform of TRβ
in tilapia (Mendoza et al., 2013) affecting
the growing processes in this specie. T3
and T2 both participate in the growth pro-
cess, however their effects are mediated by
different, specific TRβ1 isoforms (STRβ1
and LTRβ1 respectively). However, no data
are present at the moment showing that a
such binding can affect energy metabolism
in higher species and further studies are
needed to verify this possibility. Further
studies may also be useful to try to develop
new concepts that could help toward a
better understanding of some of the effects
of thyroid hormones and those of their
analogs/derivatives.
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